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Dengue is becoming recognized as one of the most important vector-borne human diseases. It is predominant in
tropical and subtropical zones but its geographical distribution is progressively expanding, making it an escalating
global health problem of today. Dengue presents with spectrum of clinical manifestations, ranging from asymptom-
atic, undifferentiated mild fever, dengue fever (DF), to dengue hemorrhagic fever (DHF) with or without shock
(DSS), a life-threatening illness characterized by plasma leakage due to increased vascular permeability. Currently,
there are no antiviral modalities or vaccines available to treat and prevent dengue. Supportive care with close moni-
toring is the standard clinical practice. The mechanisms leading to DHF/DSS remains poorly understood. Multiple
factors have been attributed to the pathological mechanism, but only a couple of these hypotheses are popular in
scientific circles. The current discussion focuses on underappreciated factors, temperature, natural IgM, and endo-
toxin, which may be critical components playing roles in dengue pathogenesis.
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Dengue, a vector-borne human disease, has been recog-
nized recently as one of the most significant public
health threats, causing high morbidity and mortality
worldwide. The disease is caused by the infection of den-
gue virus that is transmitted to human beings by the bite
of a mosquito– domestic Aedes aegypti being the princi-
pal vector– although some other species, such as Aedes
albopictus, are of importance. There are four serotypes
(DENV1, DENV2, DENV3, and DENV4), each being
capable of inducing typical dengue manifestations. The
spectrum of illness is wide, ranging from inapparent or
asymptomatic, mild febrile with varying degrees of
thrombocytopenia, hemorrhaging and increased vascular
permeability typical of dengue hemorrhagic fever (DHF),
to plasma leakage and severe shock syndrome. The re-
surgence of dengue endemicity has resulted from nu-
merous oscillating environmental, social and economical
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stated.population is at risk of dengue virus infection, with ap-
proximately 25 million of these requiring hospitalization
and about 25,000 resulting in death [1]. Currently, there
are no antiviral modalities or preventive vaccines avail-
able to alter disease outcomes. The mortality rate is
varying, ranging from 1 to 5%, dependent upon the
country and region. The exact mechanism by which
dengue virus induces plasma leakage or disease severity
remains poorly understood.
A large majority of the dengue infections occur in
humans without any noticeable illness. However there
are many incidences of symptomatic disease; they can be
partitioned into two syndromes: dengue fever (DF) and
DHF/dengue shock syndrome (DSS). While DF is a sim-
ple, self-limited febrile illness, DHF is a severe and
potentially life-threatening condition. DHF/DSS is char-
acterized by thrombocytopenia and hemorrhagic mani-
festations; additionally, there is increased vascular
permeability that leads to depleted intravascular volume
and shock. Severe, profound shock, as well as multior-
gan failure, is known to occur in extreme cases and is
associated with high mortality.
There are many excellent reviews on dengue patho-
genesis, including the topics of dengue viral biology, the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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and dengue diagnostic issues [2-7]. These aspects will
not be included in the focus of the current article;
readers who are interested in these details are encour-
aged to refer to the literature. The current article high-
lights other recent knowledge and developments in the
field, and proposes a new mechanism for biological en-
hancement to dengue pathogenesis.
Epidemiology
Initially, dengue disease predominantly affected the
people living in tropical and subtropical zones. However
the regions of the world that are endemic has spread
and the incidence in dengue disease has climbed due to
a number of contributing factors. Increased human mi-
gration is one culprit; individuals often travel between
rural areas and city dwellings and even to other coun-
tries via air travel for the purpose of making money or
personal enjoyment. A person carrying dengue virus ac-
quired in one location can be bitten again by a mosquito
and introduce it into new areas [8]. Another factor is the
weather; global warming and climate change has lead to
the augmentation of zones hospitable for mosquito sur-
vival. Issues with unplanned urban development (includ-
ing inadequate vector control and poor waste
management) have resulted in the presence of many ves-
icles for the accumulation of water, which are exploited
by Aedes aegypti for breeding and larvae/pupae produc-
tion [9,10]. All these factors have contributed to the
spread of dengue virus in endemic regions.
Recently, dengue has even been spotted in the US ter-
ritories [11]. In order to avoid a significant impact on
the world’s economy and avert potentially extensive bur-
dens to society and the public health sector, a greater
amount of research has focused on dengue virus surveil-
lance [12,13]. Consequently, as of today, dengue has
been documented in over 100 countries, increasing the
number of people at risk for an infection to 2.5 billion
people. It is estimated that 50–100 million cases of den-
gue occur annually, resulting in 250,000 -500,000 cases
of dengue hemorrhagic fever (DHF) and 25,000 deaths,
depending on epidemic activity. However, these figures
are reliant on a number of assumptions and the true in-
cidence is unknown [14-16].
Diagnosis and clinical presentation
Accurate diagnosis of dengue requires serological testing
and identification of viral material in the blood, which is
dominantly performed in the clinic. Symptomatology
cannot be relied upon because the early symptoms expe-
rienced by dengue patients are very similar to most
other tropical pathogens and common febrile illnesses.
Thus, it is very difficult for attending physicians to attri-
bute the correct pathogen to each clinical presentationwhen they are often highly variable. Once the physicians
determine the differential diagnosis, the second layer of
difficulty is to distinguish whether the patient has den-
gue fever or dengue hemorrhagic fever. The former is
likely a self-limited illness and patients normally recover
without having noticeable sequelae; in contrast, the lat-
ter, if treatment is not instituted immediately, the pro-
gression of the condition can quickly escalate and result
in life-threatening situations, including death. According
to the old WHO guidelines [17], the initial phase of clin-
ical manifestations for DF and DHF were quite similar.
In general, the onset of DF and DHF are both very
abrupt, beginning with fever. The common initial symp-
toms at the febrile stage are headache, malaise, weak-
ness, chills, aches and pains, and gastrointestinal
symptoms. Physical examination often reveals flushing
of the face, lethargy, irritability (in young children), ab-
dominal pain, hepatomegaly, and the presence of petech-
ial hemorrhages or other bleeding manifestations. Initial
complete blood counts reveal leucopenia, and after 2–5
days of fever, thrombocytopenia and depletion of coagu-
lation factors often develop.
In DF, the fever abates after 3–7 days and the patients
recover. In DHF, signs of progressive intravascular fluid
leakage, such as petechiae, ecchymosis, epistaxis, gingival
or gastrointestinal bleeding, occur after 3–5 days of
fever. Frequently, confluent petechial convalescent
rashes with scattered sparing spots develop in patients
that undergo plasma leakage, allowing doctors a way to
differentiate between DHF and typical DF. Conditions
arising from plasma leakage, including pleural effusion,
ascites, and hypoproteinaemia, are common in severe
dengue. This is the so-called critical stage, when the
fever typically begins to dissipate but the patients’ condi-
tion may worsen. At this point many patients may de-
velop shock from depletion of intravascular volume and
bleeding. Some patients deteriorate rapidly from circula-
tory failure, experiencing a condition called dengue
shock syndrome (DSS), presenting with a rapid and
weak pulse, narrow pulse pressure or hypotension, cold
clammy skin, and altered mental status. Disease severity
is classified as either mild (grades I and II) or severe
(grades III and IV), the presence of shock being the
main difference. This stage lasts no more than 48 hours,
after which the patients usually recover [16].
This WHO classification has been mostly adequate
and used for many decades; however there have been oc-
casional difficulties in classifying patients who present
with unusual manifestations. Atypical or abnormal clin-
ical presentations have been reported such as encephal-
opathy, severe hepatitis, and myocarditis, in which the
patients have severe disease but do not fit the DHF def-
inition. In 2009, WHO published another case classifica-
tion system for guiding dengue management [16]. This
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signs, dengue with warning signs, and severe dengue,
which improved sensitivity for detection but reduced
specificity [18,19]. To improve upon the specificity of
the 2009 dengue classification system, in 2011 WHO
SEARO published an amendment, which expanded case
definitions based on the previous DF/DHF (WHO 1997
[17]) description to include unusual manifestations [20].
Both WHO guidelines, the 2009 and SEARO 2011 ver-
sions, are in use in several countries. However, this is
dependent upon the country’s public health administra-
tive leaders; some advocate classifying disease according
to the new guidelines, while others still triage patients
according to the expanded older classification of DF and
DHF.
Due to the nonspecificity and complexity of dengue
patient clinical manifestations, it is imperative to con-
firm the clinical diagnosis with biological and/or labora-
tory assays. Since dengue disease management is time
sensitive, onsite rapid screening tests at the point-of-care
is a critical component in assisting decision-making. Un-
fortunately these rapid screening tests perform poorly,
having low specificities and sensitivities. Other diagnos-
tic tools, such as virus isolation or dengue virus genome,
antigen or specific IgM/IgG detection, are more inform-
ative but are also very time consuming and expensive to
perform. Even though these results do not directly con-
tribute to decisions for the patients in real time, the con-
firmatory information can provide a guideline for future
decision making on patient care in general, as well as
lead to improved precision on diagnostic rapid screening
tests under development. In addition, the results ob-
tained with confirmatory assays can serve to advance
our understanding of human dengue virus pathogenesis
and guide the development of preventive modalities.Parameters associated with DHF/DSS
Although the majority of dengue-infected individuals are
asymptomatic, a small percentage of the subjects will
progress to apparent clinical illness including life-
threatening DHF/DSS. The available information sug-
gests that multiple factors, including the presence of
cross-reactive, sub- or non-neutralizing antibodies, viral
virulence, genetic predisposition, age, nutritional status
and underlying chronic disease, can all be a risk and/or
contributive factor to the pathogenesis of DHF/DSS [21-
23]. However none of these factors has been substanti-
ated because there are no reliable in vivo model systems
to perform the necessary side-by-side comparisons. Con-
sequently, the causes of dengue disease remain poorly
understood in spite of many decades of intensive investi-
gations. Some known but under-appreciated factors are
briefly discussed here.Fever temperature
Temperature has captured the attention of the media,
owing to growing concerns about the environment and
global warming. In line with this, the change in the
global climate has significantly impacted the geographic
distribution of the mosquito vector and thus dengue dis-
ease. Accordingly, WHO has reported that a temperature
rise of only 1–2°C could increase the risk of dengue
virus infection to the population by several hundred mil-
lion, potentially resulting in 20,000–30,000 more fatal
cases annually [24]. Additionally, the biological import-
ance of temperature, particularly in the form of fever,
and its role in medical science has not received the
appropriate attention [25]. Dengue fever, as the name in-
dicates, has fever as one of its most salient clinical fea-
tures. This is also the case for many other common
febrile illnesses. The increase in body temperature during
infection is commonly viewed of as one way to interfere
with pathogen replication directly. Additionally this bio-
logical alteration may also promote the production of
the appropriate host transcriptional and translational pro-
files, which may work to eradicate some microorganisms.
Despite these known phenomena, the contribution of
fever to pathogenesis has not been investigated. Re-
searchers more frequently attribute the symptoms as dir-
ectly or indirectly caused by the pathogen rather than a
direct result of the fever. Refocusing the interpretation of
the clinical data in light of the degree of fever may allow
for a better understanding of disease presentation.
Viremia is another major finding on the pathophysi-
ology of dengue patients. Interestingly, it has been no-
ticed that viremia is correlated highly with temperature
in dengue patients [26]. A cumulative result from a pilot
study supports this observation as well (Figure 1).
Viremia kinetics are characterized by a downward trend,
with a peak in the plasma viral RNA levels correspond-
ing to the first day after onset of fever, which decreases
to undetectable levels by the 7th day of fever. The down-
ward trends in viral RNA level and body temperature
are very similar to each other and are correlated highly
with each other as a function of time (P < 0.000, R2 =
0.9535). The results were in line with reports on the
highly correlation of body temperature with viral load in
samples collected from acute dengue patients [26]. One
interpretation of this data would suggest that the lower
body temperature contributes to the clearance of
viremia. However the results could also suggest that
dengue virus may enter cells or replicate more efficiently
at higher temperatures [27,28]. Interestingly, it has been
reported that Flaviviruses in Aedes albopictus cell cul-
tures adapted to 34.5°C replicate to a higher viral titer
than those adapted to 28°C [29] and that Japanese en-
cephalitis virus yields are increased by 0.2-2.5 log PFU/
ml in heat shock-treated BHK-21 cultures at 41°C
Figure 1 Association of body temperature and viral load. Body
temperature and samples were measured from 147 walk-in patients.
Viral load was quantified by real-time RT-PCR as described elsewhere
[31]. Both body temperature and viral load decrease with time.
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why viral titers are amplified when culturing at higher
temperatures remains to be further investigated. Fore-
seeably, understanding the factors or mechanisms lead-
ing to efficient viral replication during fever, would
provide a new avenue of strategies to improve the qual-
ity of life of affected patients and perhaps a preventive
modality to dengue as well.
Biological enhancement
Pathophysiologic responses to dengue virus infection are
dynamic. Biological components circulating in the pa-
tient’s blood stream may modify the body’s physiology
and alter the presentation of the disease. The biological
response to the disease is a double-edged sword; it could
be both beneficial and harmful to the host. Shock syn-
drome often occurs during or at the end of the viral
clearance stage and is a dangerous complication of den-
gue virus infection that is associated with a high mortal-
ity rate in some countries [4]. Increased vascular
permeability is one of the remarkable clinical manifesta-
tions that have been observed in patients with severe
dengue. This event may provide a mechanism for the
translocation of microbial products from the intestinal
lumen into the circulatory system [32,33]. Although sep-
sis can be observed clinically in patients experiencing
DSS and those with bacteremia [34], the mechanism
leading to the development of dengue shock is complex
and remains largely unknown. Interestingly, gut injuryhas been correlated significantly with multiorgan failure
in hemorrhagic shock [35]. The degree of this mucosal
injury in dengue patients has been reported to correlate
with the severity of the illness [36]. Recent reports indi-
cate that more than 35% of DF patients have evidence of
bleeding in the gut as well [37]. Also, there appears to
be an escalating problem with opportunistic pathogen
infections in dengue patients (Table 1). This suggests
that substances in the gut may translocate and become
systemic. One of these such materials is lipopolysacchar-
ide (LPS) or endotoxin [38], a strong immune response
inducer. Interestingly, it has been reported that endo-
toxin is detected in 50% of serum samples collected
from DHF/DSS patients [39], and that the levels of LPS
in these samples correlate with dengue severity [40]. In a
study with cumulative data, we observed that endotoxin
levels were significantly higher in dengue patients con-
firmed with gastrointestinal bleeding (GIB) and that
48.6% of sera from acute DF patients were considered to
be endotoxin positive compared to healthy controls
(Figure 2A). Kinetic studies demonstrate that the highest
levels of endotoxin were seen at the end of disease from
days 6 to 9, during defervescence (Figure 2B); this time
point also corresponds with the critical stage, during
which patients need to be closely monitored for the oc-
currence of shock. The sera from the GIB group were
sampled from the 4th day after the onset of fever. How-
ever, although results were derived from limited patients
and the actual percentage of GIB remains unknown, lit-
erature reports have estimated that the percentage of the
GIB has been varied from regions to regions, ranging
from 1 to 39 percent [37,41,42]. Therefore, clinically,
GIB is not only largely unknown but also underesti-
mated because there may be some occult bleeding that
were overlooked and asymptomatic presentation as well.
The demographic and clinical data of the enrolled pa-
tients have been previously described [43,44].
One mechanism known to rid the blood stream of
endotoxin is through antibodies or immune complex
formation. Serum antibodies are a heterogeneous mix-
ture of immunoglobulins (Ig), all of which share the abil-
ity to bind individually to specific antigens. In mammals
there are five classes of antibody: IgA, IgD, IgE, IgG and
IgM, with 4 IgG and 2 IgA subclasses present in
humans. The IgM antibody is the first class of antibodies
produced during a primary response. Studies from mice
reared germfree and receiving an antigen-free diet have
the same serum IgM levels as mice held under conven-
tional housing conditions, while IgG and IgA levels in
these mice are greatly reduced, suggesting that a distinct
antibody, natural IgM, is induced independently of ex-
ternal stimulation [60]. Later, it was shown that IgM is
the major component of natural antibody in humans
[61,62]. The levels of natural antibodies vary among
Table 1 Escalating problems of opportunistic pathogen infections in dengue patients
Cases Pathogens Day of
fever
Reference
5 Staphylococcus aureus 8-10 [45]
4 Staphylococcus aureus, Haemophilus influenzae, Coagulase-negative staphylococcus 7-10 [46]
14 Burkholderia pseudomallei, Varicella zoster, Salmonella, Shigella, Escherichia coli, Herpes simplex, Mycobacterium
tuberculosis, Streptococcus pneumoniae, Mycoplasma pneumoniae
7-10 [47]
2 Salmonella typhi 8 [48]
1 Shigella sonnei 9 [49]
7 Rosemonas species, Klebisella pneumoniae, Moraxella lacunata, Klebisella ozaenae, Enterococcus faecalis 8-14 [50]
3 Enterococcus faecalis, Klebisella pneumoniae unspecified [51]
4 Aspergillus fumigatus 8-13 [52]
5 Plasmodium vivax, Plasmodium falciparum 3-10 [53-56]
2 Leptospira 5-7 [57,58]
1 Candida tropicalis 14 [59]
Tsai et al. Journal of Biomedical Science 2013, 20:88 Page 5 of 11
http://www.jbiomedsci.com/content/20/1/88individuals, but increase with age and with good nutri-
tion [63-65]. Characteristics of the natural IgM antibody
include low affinities and broad specificities to both for-
eign and self antigens [66]. Circulating natural IgM anti-
body provides the first line of defense against invasion
by pathogens [67-69]. Importantly, natural IgM has been
demonstrated to play an important role in the clearance
of endotoxin [70]. Pilot results from sequential samples
suggested that the levels of total IgM are dose dependent
with disease severity; DHF patients have significantly
lower levels of total IgM in sera than DF patients, inA
Figure 2 Endotoxin observed in sera of dengue patients. (A) The level
ToxinSensorTM Chromogenic LAL Endotoxin Assay Kit (GenScript USA Inc., P
high range of endotoxin levels were observed in a fraction of DF patients a
patients had endotoxin levels within the range of healthy controls. (B) The
days 6 to 9 after onset of fever.spite of similar levels of dengue specific IgM; and the
total IgM from the sera of both DF and DHF were sig-
nificantly lower than that of healthy controls (Figure 3).
The results imply that dengue patients typically have
lower IgM than that of healthy controls and possible a
reduced capability to clear LPS, lending support to the
hypothesis that endotoxin may contribute to disease
pathology.
Natural IgM is high avidity of polymeric antibody,
which may contribute to the initial immune defense and
to the control of invading pathogens until immuneB
s of endotoxin in 37 randomly chosen samples were measured by
iscataway, NJ). Two distinct patterns were observed in DF patients. A
nd in DF patients with noticeable gut bleeding, while a subset of DF
levels of endotoxin in general, increased with time, being higher on
Figure 3 Natural IgM was significantly lower in dengue patients. (A) Dengue specific IgM was measured as previously described [71].
Dengue specific IgM was only present in dengue patients. (B) Total IgM was measured as previously described [72]. The levels of total IgM were
significantly lower in both DF and DHF patients compared to healthy subjects.
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[73]. Importantly, natural IgM antibody has been shown
to directly neutralize or inhibit pathogens as well as aid
the initiation of adaptive immune response from follicu-
lar B cells, which together play critical roles in protec-
tion against bacterial and viral infection [67,69,74-76].
Consequently, despite with limited number of speci-
mens, we feel confident that the levels of the IgM in
acute dengue patients could be lower than that of
healthy subjects. Interestingly, recent evidence also suggests
that lipopolysaccharide levels are elevated in dengue virus
infected patients and correlate with disease severity [40].
One of the alternative contributing factors is the amount
of platelets. Dysfunctional platelets and thrombocytopenia
are a salient clinical finding in dengue patients and are
correlated with the severity of disease [77]. A platelet-
endotoxin interaction is a necessary step for the final re-
moval of LPS by the reticuloendothelial system [78]. The
evidence also suggests that the levels of detectable endo-
toxin in patients may be inversely correlated with the
platelet counts. Some percentage of dengue shock cases
may result from increased gut mucosa permeability, which
could lead to abnormally high endotoxin levels in the per-
ipheral blood. This phenomenon in combination with re-
duced platelet counts and reduced IgM specific to LPS
could lead to inefficient clearance of endotoxin and conse-
quently another mechanism will need to be induced to
promote its removal from the bloodstream.
Scientifically, it has been known that phagocytic cells
such as primary monocytes and macrophages are very
difficult to get infected by dengue virus [79]. But, if thesecells are pretreated with endotoxin (LPS) [80], the infect-
ivity rate increases significantly, likely as a result of en-
hanced phagocytic activity [72]. Monocytes potentially
acquire the virus when they engulf dengue-containing
platelets, a frequent occurrence in dengue patients on
days 6–8 after the onset of fever [81,82]. In addition,
LPS is known to bind to the CD14 receptor of macro-
phages and B cells and promote the secretion of pro-
inflammatory cytokines [83,84]. Interestingly, it has been
suggested that activated macrophages from secondary
DENV infected patients display enhanced phagocytic be-
havior of opsonized platelets, through a mechanism in-
volving milk fat globule-epidermal growth factor 8 [85].
Taken together, a hypothetical scenario can be drawn;
endotoxin, usually kept at a low frequency in the
circulation by functioning platelets, may leak into the
periphery through a damaged gut-endothelial barrier in
dengue patients, whom likely have dysfunctional plate-
lets, thrombocytopenia, or low natural IgM and are un-
able to clear off the endotoxin in a timely manner. This
combination of events may result in the induction of ac-
tivated macrophages or monocytes, enhancing their en-
gulfment activities and triggering a tsunami of
inflammatory cytokine production and inciting septic
shock. However this alternative hypothesis requires fur-
ther investigation.
Pre-existing immunity
The pathophysiology of severe dengue is very complex
and may involve multiple factors. Epidemiological data
tabulated from dengue endemic locales suggest that
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and/or subsequent homologous serotype infection is
known to be associated with less severe disease as com-
pared with secondary subsequent heterologous serotype
infection, a term has been coined as antibody dependent
enhancement [86]. However, our understanding of these
interacting components that contribute to the develop-
ment of dengue disease is obstructed by the lack of suit-
able animal models that can recapitulate the cardinal
features of human dengue. As a result, the exact mechan-
ism(s) leading to the development of DHF/DSS remains
poorly understood, in spite of several decades of intensive
investigations. One of the factors believed to play a role in
pathogenesis is pre-exposure. Results available from den-
gue epidemic countries have indicated that severe disease
more frequently occurs not with the primary but during
subsequent viral infections [87,88]. Without experimenta-
tion with the appropriate comparison groups and controls,
it became assumed that pre-existing immunity following a
challenge with a heterogeneous serotype is a risk for DHF/
DSS. Consequently, the hypothesis suggests that DHF/DSS
results from an abnormal or exaggerated host immune re-
sponse -– particularly due to the cross-reactive antibodies,
which bind similar epitopes on other dengue viral strains
– that augments the rate of virus uptake [4,71,89]. How-
ever, recent results accumulated from non-dengue en-
demic regions [90] and from travelers suggest that the
frequency of DHF in primary infections in naive individ-
uals is similar to that of secondary infection [91]. Also,
Libraty et al’s cohort study reveals no association between
maternal antibodies and development of severe dengue in
infants [92]. Collectively, multiple causes may play a crit-
ical role in dengue pathogenesis. The cause of pathology
in naïve individuals and in infants infected by dengue virus
may be distinctively distinguishable from that of primary
and secondary infection, respectively, in dengue epidemic
zones.
According to the WHO guidelines, it is required that
several specimens within a certain time interval be proc-
essed to clearly define the infection as primary or sec-
ondary. But, very often, in the clinical setting, multiple
sample collection is inconvenient or dangerous to col-
lect. Thus the term primary and secondary in dengue
epidemic zones are often defined with a single collection
sample by the ratio of IgM/IgG; if the value is >1.2, then
it is a primary infection, but if the value is ≤1.2, it is a
secondary. However, a very high dengue antibody preva-
lence rate of 85-95% is seen in school-aged children in
epidemic countries [88,93,94]. Also, IgG is characteris-
tically unusually low at the onset of disease in secondary
dengue patients [95]. Consequently, the definition can-
not distinguish between current infection and previous
infection. Frequently it is furthermore complicated by
samples with similar (at 1) or slightly below 1.2 ratiosfor IgM and IgG. This case is very often arbitrarily
assigned to be secondary infection, and thus the defin-
ition has been called into question [96]. To test whether
this practice can accurately distinguish between primary
and secondary sequential samples were obtained from a
cohort study. Sera were collected daily for 7 days from
30 confirmed dengue patients. The IgM/IgG ratio was
measured after antibody titers were determined. This
study indicated that if the early time point samples were
used to define the primary and secondary, then the
wrong category was often assigned since the IgM/IgG
ratios at the later time samples clearly suggested that the
allocation should be to the opposite category (Figure 4).
Although the actual percentage of the erroneous alloca-
tion of the category is unknown, primary and Secondary
dengue assignments based on the >1.2 IgM/IgG ratio
may intricate the pathogenic cause of dengue in endemic
countries. However, we observed about 26.7% (8/30) ab-
normal antibody response.in current investigation, the
percentage therefore seemed to be underestimated in
dengue epidemic zones. Thus, a better test that can dif-
ferentiate primary from secondary dengue virus infection
is urgently needed.
As a whole, evidence for the role of pre-existing im-
munity in human disease is still by and large circum-
stantial [23,97,98]. Thus, in order to further advance the
understanding of the causes of DHF/DSS, reported dis-
ease should be divided into three major categories (naïve
primary infection, defined primary infection in endemic
zones, and secondary infection) and considered separ-
ately [99]. With a clearer definition of the virus pre-
exposure history, the search for the identity of the
pathogenic cause for DHF/DSS may be much simpler to
assess and faster to acquire and likely make much more
sense.Viral strains
The occurrence of DHF/DSS in primary naïve individ-
uals and the high frequency of asymptomatic secondary
infections implicates that the immune-enhancement hy-
pothesis alone is inadequate to explain dengue patho-
genesis. An alternative explanation for the pathogenesis
of DHF/DSS is the virulence of different viral strains
[100]. Although the in vivo scientific data on the topic is
quite sparse, it can be interpreted that some dengue viral
strains are more virulent for man than others. Reports
based upon the epidemiological data advocate that par-
ticular serotypes appear to be more virulent than others
with certain ethnic groups [101-106]. In addition,
experimental results also suggest that certain genotypes
within a serotype encode determinants for virulence,
attenuation, and tissue tropism [107-111]. However,
substantiation of the virulent strain hypothesis of dengue
A B
Figure 4 Abnormal antibody response observed in sequential samples in dengue patients. Sera were collected at the indicated days and
the titers of antibodies were measured as previously described [71]. (A) Primary dengue virus infection. These samples were determined to be
from secondary patients by the IgM/IgG ratio recorded at the early acute stage. There is no robust amplification in IgG, indicating that these
patients should be recategorized as primary infections. (B) Secondary dengue virus infection. These samples were determined to be from primary
dengue patients by the IgM/IgG ratio recorded at the early acute stage. These samples demonstrate IgG amplification, indicating that these
patients should be considered secondary patients. IgM/IgG ratios, obtained at the acute stage, cannot accurately distinguish between primary
and secondary virus exposure in dengue patients.
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disease model for validation [112,113].Other factors
As aforementioned, the factors that place patients at
higher risk of developing DHF/DSS are not clearly iden-
tified yet. Multiple factors have been correlated with
DHF/DSS: age, sex, underlying disease, nutritional sta-
tus, ordering of serotype pre-exposure, individual genetic
background including HLA type and ethnic variation
[114-119]. These factors have yet to be further
evaluated.Treatment and prevention
Currently, there is not a specific antiviral treatment for
dengue. Even if there were a drug available that could re-
duce viral replication or entry it would have limited
usage. Treatment of dengue disease is time-sensitive; in
other words, as time progresses, the presence of the
virus and the ability to accurately detect it decreases,
while the risk of severe immune-mediated disease in-
creases. The best treatment currently available is imme-
diate supportive or palliative care with vigilant
monitoring by the professional healthcare staff. Patients
usually recover after fluid and electrolyte supportive
therapy. Early recognition of DHF and immediatetreatment are of utmost importance to reduce the case
fatality rate.
Since there is no antiviral therapeutic modality or vac-
cine against dengue available, the only possible prevent-
ive method that can be instituted is mosquito control.
However, the effectiveness of current insecticides is
diminishing and the successfulness of this strategy is
compromised by its high cost. Thus, a dengue vaccine is
urgently needed to prevent the virus from further
spreading.
Review; Conclusion
Dengue has been associated with human beings for
more than two centuries and yet its pathogenic cause(s)
remain poorly defined. Lack of a suitable animal model
recapitulating the cardinal features of human dengue
further hinders the progress of our understanding. Nu-
merous factors and hypotheses have been associated
with or attributed to the pathogenesis of dengue. There
are only limited results suggestive that some of these
theories may be the primal instigator of severe disease;
however they remain to be circumstantial and require
further verification. Complexity of severe dengue sug-
gests that other factors, such as fever and endotoxin, are
important as well. These factors are often underappreci-
ated and may not only provide the critical link in under-
standing the cause(s) of dengue pathogenesis, but offer a
Tsai et al. Journal of Biomedical Science 2013, 20:88 Page 9 of 11
http://www.jbiomedsci.com/content/20/1/88new strategy for the amelioration and/or prevention of
dengue.
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